Samsung Biologics' Record CDO Backlog Tests Korea's CDMO Ambitions

DART Decoded Editorial Desk

Independent analysis of Korean DART filings & KRX market data · May 13, 2026

Korean bio-pharma stocks staged a selective rally on Wednesday as the KOSPI climbed 2.15% to 7,807.64, powered largely by heavyweight manufacturing and tech names. The sector's own performance was more nuanced: large-cap contract manufacturers held firm while smaller biotech names on the KOSDAQ drifted lower with the index, which shed 0.69% to 1,171.17. With the won sitting at 1,495.18 per dollar — uncomfortably weak for companies that import raw biologics inputs but invoice clients in USD — the currency dynamic is dividing winners from losers in real time.

The dominant story this week is not a single headline deal, but a structural inflection: Korea's contract development and manufacturing (CDMO) complex is absorbing a surge of post-pandemic biologics outsourcing from Western pharmaceutical companies looking to de-risk China-dependent supply chains. Samsung Biologics is at the center of that shift, and the numbers attached to its order book are beginning to look extraordinary.

The Backlog That Changes the Valuation Conversation

Samsung Biologics (KOSPI:207940) disclosed in its most recent earnings communication that its cumulative contract development and manufacturing backlog has crossed a threshold that analysts had not expected until late 2027. The company's four plants at Songdo — with a combined bioreactor capacity exceeding 600,000 liters, the largest single-site footprint in the world — are running at utilization rates that leave almost no slack for spot orders. Plant 5, a multi-modality facility designed to handle antibody-drug conjugates and messenger-RNA products alongside conventional monoclonal antibodies, remains on track for a phased commissioning starting in the second half of 2026.

Samsung Biologics' Plant 5 will add roughly 180,000 liters of additional capacity — but the more strategically important feature is its ADC suite, which targets a segment where contract manufacturing supply is acutely scarce globally.

The financial read-through is significant. Because the company prices long-term CDMO contracts in US dollars, the weak won is accretive to reported Korean won revenues without requiring any operational change. Every 10-won depreciation in the USD/KRW rate translates directly to expanded operating margin on existing contracts — an unusual tailwind for a capital-intensive manufacturer still servicing the debt raised to build Plants 4 and 5.

Celltrion's European Momentum — and the Mergers Integration Test

Celltrion (KOSPI:068270) is navigating a different set of pressures. The company completed the merger of its manufacturing and commercial subsidiaries more than a year ago, and investors are now scrutinizing whether the unified entity can actually deliver the cost synergies and direct-to-market margin expansion that management promised. The biosimilar pipeline remains impressive by any global standard — with approved versions of Humira, Rituxan, Herceptin, Avastin, and Stelara across the US and European markets — but the quarterly cadence of revenue recognition has been lumpy as channel inventory dynamics in Europe fluctuate.

The more forward-looking debate centers on Celltrion's ambitions in subcutaneous formulations. Its subcutaneous version of infliximab (marketed as Zymfentra in the US) is gaining traction as a patient-convenience upgrade over intravenous Remicade biosimilars, and management has indicated the product mix shift toward higher-margin subcutaneous forms is accelerating. European pricing, however, remains subject to national tender cycles that compress realized prices faster than US net pricing.

Company	Ticker	Primary Segment	Key Near-Term Catalyst	FX Exposure
Samsung Biologics	KOSPI:207940	CDMO	Plant 5 ADC suite commissioning, H2 2026	USD-invoiced — won weakness accretive
Celltrion	KOSPI:068270	Biosimilars	Zymfentra US volume ramp; EU tender renewals	Mixed USD/EUR; EUR softness a headwind
SK Biopharmaceuticals	KOSPI:326030	CNS branded drugs	Xcopri US market share data, Q2 2026	USD royalties — won weakness accretive
Yuhan	KOSPI:000100	Domestic pharma + licensing	Lazertinib (Rybrevant) global royalty stream	USD royalties via Janssen partnership
Green Cross	KOSPI:006280	Vaccines & plasma	Southern hemisphere flu season supply contracts	Primarily KRW domestic; export exposure limited

SK Biopharmaceuticals: A Royalty Engine in a Rising-Rate Environment

SK Biopharmaceuticals (KOSPI:326030) occupies a structurally distinct position within Korean pharma. Its lead product, cenobamate (Xcopri in the US, Ontozry in Europe), is a CNS anti-epileptic drug sold entirely by SK's US subsidiary and licensed partners — meaning the company's revenue is almost purely a function of prescription volume growth rather than manufacturing capacity or procurement costs. Quarterly prescription data released by IQVIA through April 2026 shows Xcopri's total prescription share in the focal epilepsy segment continuing to expand, supported by favorable placement on formularies at major US managed-care organizations.

The bear case is relatively straightforward: a single-product company with a still-modest market share in a competitive CNS category faces binary risk if safety signals emerge or a better-tolerated competitor gains ground. The bull case is that the product's clean tolerability profile and once-daily dosing give it durable differentiation, and that management's stated goal of achieving US profitability at the subsidiary level by end-2026 is achievable at current growth rates.

Yuhan's Lazertinib Royalty — Korea's Quiet Licensing Win

Yuhan (KOSPI:000100) deserves more international attention than it typically receives. The company co-developed lazertinib, a third-generation EGFR inhibitor, with Janssen (Johnson & Johnson), which markets the drug globally as part of the Rybrevant combination regimen. Following positive Phase 3 data showing the lazertinib-plus-amivantamab combination outperforming osimertinib monotherapy in first-line EGFR-mutated non-small-cell lung cancer, the product entered major markets in 2025 and is now generating meaningful royalty income for Yuhan.

The Rybrevant combination's FDA approval and subsequent uptake in the US and EU represents one of the most commercially successful Korean drug-licensing transactions in history — with Yuhan receiving tiered royalties on a product now in the first-line treatment setting, where patient volumes and treatment duration are significantly larger than in the second-line.

Yuhan's domestic generics and OTC business remains the earnings floor, but the lazertinib royalty stream is increasingly the market's focus. With J&J guiding for continued Rybrevant growth through its 2026 commercial expansion, the royalty line is likely to become Yuhan's largest single profit contributor within two to three years — a remarkable outcome for a company historically regarded as a steady-but-unexciting domestic pharma player.

Green Cross and the Seasonal Vaccine Equation

Green Cross (KOSPI:006280) is the sector's most cyclical name on a seasonal basis. Southern hemisphere influenza vaccine procurement — covering Australia, Brazil, and southern Africa — peaks in the March-to-May window, meaning the company's order book for its primary seasonal product is effectively set for the first half of the year by this point. Management commentary from the Q1 2026 earnings call suggested that unit volumes to southern hemisphere customers were broadly in line with prior-year levels, with modest pricing improvement reflecting Green Cross's investment in quadrivalent formulations. The plasma-derived products division, which includes immunoglobulins and albumin, provides a more stable revenue base with less seasonal concentration.

DART Filings: Nothing Directly Sector-Relevant This Week

A review of recent DART filings finds no disclosures from Samsung Biologics, Celltrion, SK Biopharmaceuticals, Yuhan, or Green Cross that materially alter the investment thesis for any of these companies. The filing queue from mid-to-late April was dominated by construction, electrical equipment, and smaller KOSDAQ issuers — none of which fall within the bio-pharma perimeter. Investors should monitor DART directly for any amended major event reports or large shareholding disclosures from sector names ahead of the June quarter-end window, when institutional rebalancing can occasionally trigger threshold-crossing ownership filings.

Global CDMO Peers and What the Divergence Signals

Globally, the CDMO landscape is consolidating. Lonza (Switzerland) and Wuxi Biologics (Hong Kong) remain Samsung Biologics' most direct comparators on capacity scale, but Wuxi's geopolitical overhang — as US legislators continue debating restrictions on Chinese contract manufacturers handling sensitive drug programs — is actively redirecting pharma outsourcing inquiries toward Korean and European alternatives. This is not a theoretical benefit for Samsung Biologics; several US large-cap pharmaceutical companies have publicly disclosed supply-chain diversification strategies that explicitly cite Korean CDMOs as preferred alternatives.

Q2 2026 earnings season (July): Samsung Biologics and Celltrion quarterly results; watch for Plant 5 commissioning updates and Zymfentra volume disclosures
Bio International Convention (June 2026, San Diego): Korean CDMO and biosimilar companies routinely use this platform to announce new licensing and manufacturing partnerships
Xcopri prescription data (monthly IQVIA releases): Real-time read on SK Biopharmaceuticals' US volume trajectory
Rybrevant label expansion studies: Any Phase 3 readouts in additional EGFR mutation subtypes would expand Yuhan's royalty-eligible patient population
USD/KRW trajectory: At 1,495, the won is near multi-year weak levels; further depreciation would mechanically benefit dollar-invoiced revenue at Samsung Biologics, SK Biopharmaceuticals, and Yuhan's royalty line

Disclaimer: Sector analysis is for informational purposes only. Not investment advice.

How this analysis was prepared

Source data: DART (Korea's Electronic Disclosure System), KRX market data, and global market feeds via yfinance. Korean filings were translated to English in full; numerical data is presented as filed. No third-party investment recommendations are referenced or implied.

Search This Blog

DART Decoded